Exhibit 10.56

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 26,
2014, is by and among Alimera Sciences, Inc. (the “Company”) and Deerfield
Private Design Fund II, L.P., Deerfield Private Design International II, L.P.,
Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P.
and Deerfield Special Situations Fund International Master Fund, L.P.
(collectively the “Investors”).

RECITALS
WHEREAS, the Company has filed with the Securities and Exchange Commission (the
“Commission”) the Registration Statement (as defined below) relating to the
offer and sale from time to time of the Company’s securities, including shares
of its common stock, par value $0.01 per share (the “Common Stock”) and shares
of its preferred stock, par value $0.01 per share (“Preferred Stock”);
WHEREAS, the Board of Directors of the Company has authorized the creation of a
new series of Preferred Stock denominated as Series B Convertible Preferred
Stock (“Series B Preferred Stock”);
WHEREAS, the Company is offering for sale shares of Series B Preferred Stock and
the Conversion Shares (as defined below) pursuant to the Registration Statement;
WHEREAS, the Investors desire to purchase from the Company shares of Series B
Preferred Stock on the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing recitals (which are deemed to
be a part of this Agreement), mutual covenants, representations, warranties and
agreements contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:
1.Definitions. As used herein, the following terms have the meanings indicated:
“Aggregate Purchase Price” shall have the meaning set forth in Section 2(a)
hereof.
“Business Day” means any day other than Saturday, Sunday or a day on which banks
in the City of New York are authorized or required to be closed.
“Certificate of Designation” means the Certificate of Designation of
Preferences, Rights and Limitations of the Series B Convertible Preferred Stock,
in the form attached hereto as Exhibit A.
“Common Stock Equivalents” shall mean any securities of the Company which would
entitle the holder thereof to acquire, directly or indirectly, at any time
Common Stock, including, without limitation, any debt, preferred stock, rights,
options, warrants or other

--------------------------------------------------------------------------------

instrument that is at any time convertible into or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock or other
securities that entitle the holder to receive, directly or indirectly, Common
Stock.
“Conversion Shares” shall mean shares of Common Stock issuable upon conversion
of Series B Preferred Stock.
“Investor Shares” means 8,416.252 shares of Series B Preferred Stock.
“knowledge” means with respect to any statement made to the Company’s knowledge,
that statement is based upon the actual knowledge of the Company or its Chief
Executive Officer or Chief Operating Officer and Chief Financial Officer.
“Loss” shall have the meaning set forth in Section 5 hereof.
“Material Adverse Effect” shall mean a material adverse effect on (a) the
business, operations, financial condition or assets of the Company or its
subsidiaries taken as a whole, (b) the validity or enforceability of any
provision of this Agreement, or (c) the rights and remedies of the Investors
under this Agreement.
“Person” shall mean any individual, partnership, limited liability company,
joint venture, firm, corporation, association, trust or other enterprise or any
government or political subdivision or any agency, department or instrumentality
thereof.
“Principal Trading Market” shall mean whichever of the New York Stock Exchange,
the NYSE Alternext (formerly the American Stock Exchange), the NASDAQ Global
Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or the OTC
Bulletin Board on which the Common Stock is listed or quoted for trading on the
date in question.
“Prospectus” shall have the meaning set forth in Section 4(b)(7) hereof.
“Prospectus Supplement” shall mean the prospectus supplement to be filed with
the Commission regarding the Investor Shares and the Conversion Shares pursuant
to Rule 424(b) promulgated under the Securities Act (“Rule 424(b)”) and deemed
to be part of the Registration Statement at the time of effectiveness.
“Registration Statement” shall mean the registration statement on Form S‑3 (File
No. 333-198044), including a prospectus, and including all amendments and
supplements thereto (including the Prospectus Supplement), relating to the offer
and sale of certain of the Company’s Common Stock, Preferred Stock, Debt
Securities and Warrants, including the Investor Shares and the Conversion
Shares. References herein to the term “Registration Statement” as of any date
shall mean such effective registration statement, as amended or supplemented to
such date, including all information and documents incorporated by reference
therein as of such date.
“Securities Act” shall mean the Securities Act of 1933, as amended.

    
2

--------------------------------------------------------------------------------

2.    Purchase of Series B Preferred Stock.
(a)    Subject and pursuant to the terms and conditions set forth in this
Agreement, the Company agrees that it will issue and sell to the Investors, and
the Investors agree that they will purchase from the Company, the number of
Investor Shares set forth after their name on Schedule 1 attached hereto in the
column headed “Number of Shares of Series B Preferred Stock to be Purchased by
Investor Pursuant to Section 2(a)” at a purchase price of $6,030 for each
Investor Share and an aggregate purchase price of $50,000,000 (the “Aggregate
Purchase Price”). The closing of the purchase and sale of the Investor Shares
will take place not more than fifteen (15) Business Days following the date of
this Agreement, or such other date or time as the parties may agree upon in
writing (the “Closing”).
(b)    At the Closing, the Investors shall be entitled to receive a subscription
premium equal to 1.5% of the Aggregate Purchase Price which shall be payable by
the issuance of additional Investor Shares as set forth on Schedule 1 hereto.
3.    Deliveries at Closing.
(a)    Deliveries by the Investor. At the Closing, each Investor shall deliver
to the Company the Aggregate Purchase Price set forth next to its name on
Schedule 1 hereto by wire transfer of immediately available funds to a bank
account designated in writing by the Company to the Investors, which funds will
be delivered to the Company in consideration of the Investor Shares issued at
the Closing.
(b)    Deliveries by the Company. At the Closing, the Company shall
(1)    deliver to each Investor stock certificates in a form, reasonably
satisfactory to the Investors, registered in the name of such Investor
evidencing the number of shares of Series B Preferred Stock issuable to such
Investor; and
(2)    deliver evidence satisfactory to the Investors, that the Certificate of
Designation has been filed with the Secretary of State of Delaware and has
become effective on or prior to the Closing.
4.    Representations, Warranties, Covenants and Agreements.
(a)    Investor Representations, Warranties and Covenants. Each Investor
represents, warrants, covenants and agrees as follows as of the date hereof and
as of the Closing:
(3)    Investor has received and reviewed copies of the Registration Statement
and the Prospectus, including all documents and information incorporated by
reference therein and amendments thereto, and understands that no Person has
been authorized to give any information or to make any representations that were
not contained in the Registration Statement and the Prospectus, and Investor has
not relied on any such other information or representations in making a decision
to acquire the Investor Shares. Investor hereby consents to receiving delivery
of the Registration Statement and the Prospectus, including all documents and
information incorporated by reference therein and amendments thereto, by
electronic mail or by

    
3

--------------------------------------------------------------------------------

accessing the EDGAR database on the Commission’s website. Investor understands
that an investment in the Company involves a high degree of risk for the
reasons, among others, set forth under the caption “Risk Factors” in the
Prospectus.
(4)    Investor acknowledges that it has sole responsibility for its own due
diligence investigation and its own investment decision, and that in connection
with its investigation of the accuracy of the information contained or
incorporated by reference in the Registration Statement and the Prospectus and
its investment decision, Investor has not relied on any representation or
information, as the case may be, not set forth in this Agreement, the
Registration Statement or the Prospectus, or any Person affiliated with the
Company or on the fact that any other Person has decided to purchase the
Investor Shares.
(5)    The execution and delivery of this Agreement by Investor and the
performance of this Agreement and the consummation by Investor of the
transactions contemplated hereby have been duly authorized by all necessary
corporate or partnership action of Investor, as applicable, and this Agreement,
when duly executed and delivered by Investor, will constitute a valid and
legally binding instrument, enforceable in accordance with its terms against
Investor, except as enforcement hereof may be limited by the effect of any
applicable bankruptcy, insolvency, reorganization or similar laws or court
decisions affecting enforcement of creditors’ rights generally and except as
enforcement hereof is subject to general principles of equity (regardless of
whether enforcement is considered in a proceeding in equity or at law).
(b)    Company Representations, Warranties and Covenants. The Company hereby
represents, warrants, covenants and agrees as follows as of the date hereof and
as of the Closing:
(1)    The Company has been duly incorporated and is validly existing as a
corporation under the laws of the State of Delaware, with corporate power and
authority to own its properties and conduct its business as described in the
Prospectus, and has been duly qualified as a foreign corporation for the
transaction of business and is in good standing under the laws of each other
jurisdiction in which it owns or leases properties or conducts any business so
as to require such qualification, except for such jurisdictions wherein the
failure to be so qualified and in good standing would not individually or in the
aggregate have a Material Adverse Effect.
(2)    Each subsidiary of the Company has been duly incorporated or organized
and is validly existing in good standing (to the extent the concept of good
standing exists in the subsidiary’s jurisdiction or incorporation or
organization) under the laws of its jurisdiction of incorporation or
organization, with power and authority to own its properties and conduct its
business as described in the Prospectus, and has been duly qualified for the
transaction of business and is in good standing under the laws of each other
jurisdiction in which it owns or leases properties or conducts any business so
as to require such qualification, except for such jurisdictions wherein the
failure to be so qualified and in good standing would not individually or in the
aggregate have a Material Adverse Effect. Except as disclosed by the Company’s
periodic reports filed with the Commission and except as required pursuant to
this Agreement and as of the date of the most recent quarterly report filed by
the Company, there are no outstanding (i) securities of the Company or any of
the subsidiaries of the Company which are convertible into or exchangeable for
shares of capital stock or voting securities of any subsidiary of the Company or
(ii) options or other rights to

    
4

--------------------------------------------------------------------------------

acquire from the Company or any subsidiary of the Company, or other obligation
of the Company or any subsidiary of the Company to issue, any capital stock,
voting securities or securities convertible into or exchangeable for capital
stock or voting securities of any subsidiary of the Company (collectively, the
“Subsidiary Securities”). There are no outstanding obligations of the Company or
any subsidiary of the Company to repurchase, redeem or otherwise acquire any
outstanding Subsidiary Securities.
(3)    The execution, delivery and performance of this Agreement by the Company
and the consummation of the transactions contemplated hereby are within the
corporate powers of the Company and have been duly authorized by all necessary
corporate action on the part of the Company and this Agreement, when duly
executed and delivered by the parties hereto, will constitute a valid and
legally binding instrument of the Company enforceable in accordance with its
terms, except as enforcement hereof may be limited by the effect of any
applicable bankruptcy, insolvency, reorganization or similar laws or court
decisions affecting enforcement of creditors’ rights generally and except as
enforcement hereof is subject to general principles of equity (regardless of
whether enforcement is considered in a proceeding in equity or at law).
(4)    The Investor Shares have been duly authorized by the Company, and when
issued and delivered by the Company against payment therefor as contemplated by
this Agreement will be validly issued, fully paid and nonassessable, and will
conform to the description of the Series B Preferred Stock contained in the
Prospectus. The Investor Shares and the Conversion Shares will be issued in
compliance with all federal and state securities laws.
(5)    The Company has reserved from its duly authorized capital stock a number
of shares of Common Stock sufficient for issuance of all of the Conversion
Shares. The Conversion Shares, when issued, will have been duly authorized and,
when issued, delivered and paid for in accordance with the terms of the
Certificate of Designation, will have been validly issued and will be fully paid
and nonassessable. The Company shall, so long as any of the Series B Preferred
Stock is outstanding, take all action necessary to reserve and keep available
out of its authorized and unissued capital stock, solely for the purpose of
effecting the conversion of the Series B Preferred Stock, the number of shares
of Common Stock issuable upon such conversion (without taking into account any
limitations on the conversion of the Series B Preferred Stock set in the
Certificate of Designation).
(6)    The execution and delivery of this Agreement do not, and the compliance
by the Company with the terms hereof will not, (i) violate the Certificate of
Incorporation (as amended to date) of the Company or the By‑Laws (as amended to
date) of the Company, (ii) result in a breach or violation of any of the terms
or provisions of, or constitute a material default under, any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to
which the Company or any of its subsidiaries is a party or by which the Company
or any of its subsidiaries is bound or to which any of their properties or
assets are subject, or (iii) result in a violation of, or failure to be in
compliance with, any applicable statute or any order, judgment, decree, rule or
regulation of any court or governmental, regulatory or self-regulatory agency or
body having jurisdiction over the Company or any of its subsidiaries or any of
their properties or assets, except where such breach, violation, default or the
failure to be in compliance would not individually or in the aggregate have a
Material Adverse Effect or adversely affect the ability of the Company to issue
and sell the Investor Shares; and no consent,

    
5

--------------------------------------------------------------------------------

approval, authorization, order, registration, filing or qualification of or with
any such court or governmental, regulatory or self-regulatory agency or body is
required for the valid authorization, execution, delivery and performance by the
Company of this Agreement or the issuance of the Investor Shares, except for the
filing of one or more Form 8-Ks, the filing of the Prospectus Supplement, the
filing of the Certificate of Designation (which is required to be filed and
effective prior to the Closing in accordance with Section 3(b)(2) hereof), the
filing of a Notification of Listing of Additional Shares with The NASDAQ Stock
Market LLC, and for such consents, approvals, authorizations, registrations,
filings or qualifications as may be required under state securities or “blue
sky” laws.
(7)    The Company meets the requirements for use of Form S-3 under the
Securities Act. The Registration Statement, which covers the Investor Shares and
the Conversion Shares, including a form of prospectus and such amendments or
supplements to such Registration Statement as may have been required prior to
the date of this Agreement, has been prepared by the Company under the
provisions of the Securities Act, has been filed with the Commission, has become
effective and filed with the Commission and incorporates by reference documents
which the Company has filed in accordance with the provisions of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”). The Company has prepared
a Prospectus Supplement to the prospectus included in the Registration Statement
referred to above, setting forth the terms of the offering and sale of the
Investor Shares and additional information concerning the Company and its
business and will promptly file the Prospectus Supplement with the Commission
pursuant to Rule 424(b). No stop order suspending the effectiveness of the
Registration Statement or any post-effective amendment thereto, or any part
thereof, has been issued and served on the Company, and no proceedings for that
purpose are pending or, to the knowledge of the Company, threatened by the
Commission. The form of prospectus included in the Registration Statement as of
the date hereof, as amended or supplemented from time to time (including the
Prospectus Supplement), is referred to herein as the “Prospectus.” Any reference
herein to the Registration Statement, the Prospectus or any amendment or
supplement thereto shall be deemed to refer to and include the documents
incorporated (or deemed to be incorporated) by reference therein, and any
reference herein to the terms “amend,” “amendment” or “supplement” with respect
to the Registration Statement or Prospectus shall be deemed to refer to and
include the filing after the execution hereof of any document with the
Commission deemed to be incorporated by reference therein. As of the close of
business on November 26, 2014, at least a number of shares of Preferred Stock
and Common Stock equal to the number of Investor Shares and Conversion Shares,
respectively, were available for issuance pursuant to the Registration
Statement, which permits the issuance of the Investor Shares and the Conversion
Shares in the manner contemplated by this Agreement.
Each part of the Registration Statement, when such part became or becomes
effective, and the Prospectus and any amendment or supplement thereto, on the
date of filing thereof with the Commission and at the date hereof and the date
of the Closing, did or will in all material respects comply with all applicable
provisions of the Securities Act and the Exchange Act. Each part of the
Registration Statement, when such part became or becomes effective, did not or
will not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the
statements therein not misleading. The Prospectus and any amendment or
supplement thereto, on the date of filing thereof with the Commission, did not
or will not contain any untrue statement of a material fact or omit to state a

    
6

--------------------------------------------------------------------------------

material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, and any statutes,
regulations, contracts or other documents that are required to be described in
the Registration Statement or Prospectus or to be filed as exhibits to the
Registration Statement have been so described or filed.
(8)    The consolidated financial statements and financial schedules of the
Company included or incorporated by reference in the Registration Statement and
the Prospectus have been prepared in conformity with generally accepted
accounting principles (except, with respect to the unaudited consolidated
financial statements, for the footnotes and subject to customary audit
adjustments) applied on a consistent basis, are consistent in all material
respects with the books and records of the Company, and accurately present in
all material respects the consolidated financial position, results of operations
and cash flow of the Company and its subsidiaries as of and for the periods
covered thereby.
(9)    Neither the Company nor any of its subsidiaries has sustained since the
respective dates of the latest audited financial statements included or
incorporated by reference in the Registration Statement and Prospectus any
material loss or interference with its business from fire, explosion, flood or
other calamity, whether or not covered by insurance, or from any labor dispute
or court or governmental action, order or decree, otherwise than as disclosed in
or contemplated by the Registration Statement and Prospectus; and, since the
respective dates as of which information is given in the Registration Statement
and Prospectus, other than as contemplated in this Agreement, there has not been
any material change in the capital stock or long-term debt of the Company or any
of its subsidiaries.
(10)    Other than as disclosed in the Prospectus, there are no legal,
governmental or regulatory proceedings pending to which the Company or any of
its subsidiaries is a party or of which any material property of the Company or
any of its subsidiaries is the subject which, taking into account the likelihood
of the outcome, the damages or other relief sought and other relevant factors,
would individually or in the aggregate reasonably be expected to have a Material
Adverse Effect or adversely affect the ability of the Company to issue and sell
the Investor Shares, and no such proceedings are threatened in writing to the
Company or, to the Company’s knowledge, have been contemplated by governmental
or regulatory authorities or threatened by others.
(11)    The Company and each of its subsidiaries have title to all the real
property, and owns all other properties and assets, reflected as owned in the
financial statements included or incorporated by reference in the Registration
Statement and the Prospectus, subject to no lien, mortgage, pledge, charge or
encumbrance of any kind except those, if any, reflected in such financial
statements or disclosed in the Company’s filings with the Commission or exhibits
thereto, or which are not material to the Company and its subsidiaries taken as
a whole. The Company and each of its subsidiaries hold their respective leased
real and personal properties under valid and binding leases, except where the
failure to do so would not reasonably be expected to individually or in the
aggregate have a Material Adverse Effect.
(12)    The Company has filed all necessary federal and state income and
franchise tax returns and has paid all taxes shown as due thereon or has filed
all necessary extensions,

    
7

--------------------------------------------------------------------------------

and there is no tax deficiency that has been, or to the knowledge of the Company
could reasonably be expected to be, asserted against the Company or any of its
properties or assets that would in the aggregate or individually reasonably be
expected to have a Material Adverse Affect.
(13)    There are no holders of securities of the Company having preemptive
rights to purchase Common Stock. There are no holders or beneficial owners of
securities of the Company having rights to registration thereof whose securities
have not been previously registered or who have not waived such rights with
respect to the registration of the Company’s securities on the Registration
Statement, except where the failure to obtain such waiver would not individually
or in the aggregate reasonably be expected to have a Material Adverse Effect.
(14)    The issuance of the Investor Shares and the Conversion Shares will not
obligate the Company to issue shares of Common Stock or other Common Stock
Equivalents to any Person (other than the Investors), will not trigger any
preemptive or other rights to subscribe for or purchase securities and will not
result in a right of any holder of Company securities to adjust the exercise,
conversion, exchange or reset price or other right under any of such securities.
(15)    The Company is not, and does not intend to conduct its business in a
manner in which it would become, an “investment company” as defined in
Section 3(a) of the Investment Company Act of 1940, as amended.
(16)    The Company is in compliance in all material respects with all listing
and maintenance requirements of the Principal Trading Market. The issuance and
sale of the Investor Shares and the issuance of the Conversion Shares will, at
the time of such issuance and sale, comply in all material respects with and
will not contravene the rules and regulations of the Principal Trading Market.
The Conversion Shares, when issued, will be listed for trading on the Principal
Trading Market.
5.    Indemnification.
(a)    Subject to the limitations and other provisions of this Section 5, the
Company covenants and agrees to indemnify, defend and hold harmless the
Investors and their respective directors, officers, partners, managers,
employees and agents (each, an “Investor Party”) from and against any and all
Losses arising from claims by third parties resulting from, incurred in
connection with or arising out of (but only to the extent of) (a) any breach of
any representation, warranty or covenant of the Company contained herein, or (b)
the failure of the Company to perform any of the agreements, covenants or
obligations contained herein (other than if any such claim was a result of a
breach by the Investor hereunder). Subject to the limitations and other
provisions of this Section 5, the Investor covenants and agrees to indemnify,
defend and hold harmless the Company from and against (but only to the extent
of) any and all Losses arising from claims by third parties resulting from,
incurred in connection with or arising out of (but only to the extent of) (a)
any breach of any representation or warranty of the Investor contained herein,
or (b) the failure of the Investor to perform any of the agreements, covenants
or obligations of the Investor contained herein. The term “Loss” or any similar
term shall mean any and all damages, deficiencies, costs, claims, fines,
judgments, amounts paid in settlement,

    
8

--------------------------------------------------------------------------------

expenses of investigation, interest, penalties, taxes, assessments,
out-of-pocket expenses (including reasonable attorneys’ and auditors’ fees and
disbursements, witness fees and court costs) but specifically excluding
consequential, special, punitive, multiple and other similar damages. The party
or parties being indemnified are referred to herein as the “Indemnitee” and the
indemnifying party is referred to herein as the “Indemnitor.”
(b)    Indemnification Procedure.
(1)    Any party who receives notice of a potential claim that may, in the
judgment of such party, result in a Loss shall use all reasonable efforts to
provide the parties hereto notice thereof within fifteen (15) days of the filing
or other written assertion of any such claim against the Indemnitee, provided
that failure or delay or alleged delay in providing such notice shall not
adversely affect such party’s right to indemnification hereunder, unless and
then only to the extent that such failure or delay or alleged delay has resulted
in actual prejudice to the Indemnitor, including, without limitation, by the
expiration of a statute of limitations. In the event that any party shall incur
or suffer any Losses in respect of which indemnification may be sought by such
party hereunder, the Indemnitee shall assert a claim for indemnification by
written notice (a “Notice”) to the Indemnitor stating the nature and basis of
such claim.
(2)    In the case of third party claims for which indemnification is sought,
the Indemnitor shall, if necessary, retain counsel reasonably satisfactory to
the Indemnitee, and have the option (i) to conduct any proceedings or
negotiations in connection therewith, (ii) to take all other steps to settle or
defend any such claim (provided that the Indemnitor shall not settle any such
claim without the consent of the Indemnitee which consent shall not be
unreasonably withheld or delayed) and (iii) to employ counsel to contest any
such claim or liability in the name of the Indemnitee or otherwise. In any
event, the Indemnitee shall be entitled to participate at its own expense and by
its own counsel in any proceedings relating to any third party claim. The
Indemnitor shall, within fifteen (15) Business Days of receipt of the Notice,
notify the Indemnitee of its intention to assume the defense of such claim. If
(i) the Indemnitor shall decline to assume the defense of any such claim, (ii)
the Indemnitor shall fail to notify the Indemnitee within fifteen (15) Business
Days after receipt of the Notice of the Indemnitor’s election to defend such
claim or (iii) in the reasonable opinion of counsel for the Indemnitee, the
representation by the same counsel of the Indemnitor and the Indemnitee would be
inappropriate due to actual or potential material differing interests between
such Indemnitee and any other party represented by such counsel in such
proceeding, then in each such case the Indemnitor shall not have the right to
direct the defense of such action on behalf of the Indemnitee and the Indemnitee
shall, at the sole expense of the Indemnitor, defend against such claim;
provided, that the Indemnitee may not settle such claim without the consent of
the Indemnitor (which consent will not be unreasonably withheld or delayed). In
such event, the Indemnitor shall pay for only one separate legal counsel for the
Indemnitees, and such legal counsel shall be selected by the Indemnitee. The
reasonable expenses of all proceedings, contests or lawsuits in respect of such
claims shall be borne and paid by the Indemnitor if the Indemnitee is entitled
to indemnification hereunder and the Indemnitor shall pay the Indemnitee, in
immediately available funds, the amount of any Losses, within a reasonable time
of the incurrence of such Losses. Regardless of which party shall assume the
defense or negotiation of the settlement of the claim, the parties agree to
cooperate fully with one another in connection therewith. Anything in this
Section 5 to the contrary notwithstanding, the Indemnitor shall not,

    
9

--------------------------------------------------------------------------------

without the Indemnitee’s prior written consent, settle or compromise any claim
or consent to entry of any judgment in respect thereof which imposes any future
obligation on the Indemnitee or which does not include, as an unconditional term
thereof, the giving by the claimant or plaintiff to the Indemnitee, a release
from all liability in respect of such claim.
(c)    No Waiver. Nothing herein shall in any way limit a Party’s remedies in
respect of a breach of any representation, warranty or covenant hereunder.
6.    Conditions.
(a)    The obligation of each Investor to purchase and acquire the Investor
Shares hereunder shall be subject to the conditions that:
(3)    All representations and warranties of the Company herein shall be true
and correct in all material respects as of and on each of the date of this
Agreement and the date of the Closing;
(4)    The Company shall have performed all of its obligations hereunder;
including delivery of certificates for the Series B Preferred Stock;
(5)    The Prospectus Supplement shall have been filed with the Commission
pursuant to Rule 424(b) within the applicable time period prescribed for such
filing, no stop order suspending the effectiveness of the Registration Statement
or any part thereof shall have been issued and no proceeding for that purpose
shall have been initiated or threatened by the Commission, and the Investor
shall have received the Prospectus in accordance with the federal securities
laws.
(b)    The obligation of the Company to sell the Investor Shares hereunder shall
be subject to the conditions that:
(1)    All representations and warranties and other statements of the Investors
herein shall be true and correct in all material respects as of and on each of
the date of this Agreement and the date of the Closing;
(2)    The Investors shall have performed all of their obligations hereunder.
7.    Covenants.
(a)    Fees and Costs. The Company will reimburse the Investors for reasonable,
documented expenses for attorneys, accountants and other professional advisors,
and other out-of-pocket expenses incurred by Investors in connection with their
due diligence, negotiation and documentation of the transactions contemplated up
to an aggregate amount of $200,000.
(b)    The Company shall, so long as any of the Investor Shares is outstanding,
take all action necessary to reserve and keep available out of its authorized
and unissued capital stock, solely for the purpose of effecting the conversion
of the Investor Shares, the number of

    
10

--------------------------------------------------------------------------------

shares of Common Stock issuable upon such conversion (without taking into
account any limitations on the conversion of the Series B Preferred Stock set
forth in the Certificate of Designation), free and clear of all encumbrances and
restrictions. The Company shall cause the Conversion Shares, when issued in
accordance with the provisions of the Certificate of Designation, to be duly
authorized, validly issued and fully paid and non-assessable.
8.    Miscellaneous.
(a)    Binding Agreement; Assignment. This Agreement shall be binding upon, and
shall inure solely to the benefit of, each of the parties hereto, and each of
their respective heirs, executors, administrators, successors and assigns, and
no other person other than Indemnitees shall acquire or have any right under or
by virtue of this Agreement. The Company may not assign any of its rights or
obligations hereunder to any other person or entity without the prior written
consent of the Investors.
(b)    Entire Agreement. This Agreement and the Certificate of Designation,
including the Schedules and Exhibits hereto constitute the entire understanding
between the parties hereto with respect to the subject matter hereof and may be
amended only by written execution by both parties. Upon execution by the Company
and the Investors, this Agreement shall be binding on each of the parties
hereto.
(c)    Consent To Jurisdiction. THIS AGREEMENT SHALL BE ENFORCED, GOVERNED AND
CONSTRUED IN ALL RESPECTS IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK,
WITHOUT GIVING EFFECT TO ITS CONFLICTS OF LAWS PRINCIPLES OTHER THAN SECTIONS
5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF SUCH STATE. FURTHERMORE, THE
INVESTOR HEREBY IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE FEDERAL OR STATE
COURTS LOCATED IN THE STATE OF NEW YORK IN ANY LEGAL PROCEEDING ARISING OUT OF
OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF
THE COMPANY AND THE INVESTORS (AND, TO THE EXTENT PERMITTED BY LAW, ON BEHALF OF
ITS AND THEIR EQUITY HOLDERS AND CREDITORS) HEREBY KNOWINGLY, VOLUNTARILY AND
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY
CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE
TRANSACTIONS CONTEMPLATED HEREBY.
(d)    Notices. Any notice, request or other communication to be given or made
under this Agreement shall be in writing. Such notice, request or other
communication shall be deemed to have been duly given or made when it shall be
delivered by hand, overnight mail, international courier (confirmed by
facsimile), electronic mail or facsimile to the Party to which it is required or
permitted to be given or made at such Party’s address specified below or at such
other address as such Party shall have designated by notice to the other
Parties.
If to the Borrower:
Alimera Sciences, Inc.
    6210 Windward Parkway, Suite 290
    Alpharetta, GA 30005
    E-mail: rick.eiswirth@alimerasciences.com
    Attention: Richard S. Eiswirth, Jr., Chief Financial Officer and Chief
Operating Officer

    
11

--------------------------------------------------------------------------------

With a copy to:
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
One Marina Park Drive, Suite 900
Boston, MA 02210
Fax: (617) 648-9199
Email: ggriner@gunder.com
Attn: Gregg A. Griner, Esq.
If to the Purchasers:
Deerfield Management Company, L.P.
780 Third Avenue, 37th Floor
New York, NY 10017
Fax: (212) 599-3075
Email: dclark@deerfield.com
Attn: David J. Clark

With a copy to:
Katten Muchin Rosenman LLP
575 Madison Avenue
New York, New York 10022
Fax: (212) 940-8776
Email: mark.fisher@kattenlaw.com
Attn: Mark I. Fisher, Esq.

or to such other Person at such other place as the parties shall designate to
one another in writing.
(e)    Counterparts. This Agreement maybe executed in any number of counterparts
and by the parties hereto in separate counterparts, each of which when so
executed shall be deemed to be an original and all of which taken together shall
constitute one in the same agreement.
(f)    Telecopy Execution and Delivery. A facsimile, electronic mail, telecopy,
PDF or other reproduction of this Agreement may be executed by one or more
parties hereto, and an executed copy of this Agreement may be delivered by one
or more parties by facsimile, e-mail or similar electronic transmission device
pursuant to which the signature of or on behalf of such party can be seen, and
such execution and delivery shall be considered valid, binding and effective for
all purposes. At the request of any party, all parties agree to execute an
original of

    
12

--------------------------------------------------------------------------------

this Agreement as well as any facsimile, telecopy or reproduction thereof. The
parties hereto hereby agree that neither shall raise the execution of facsimile,
telecopy, PDF or other reproduction of this Agreement, or the fact that any
signature or document was transmitted or communicated by facsimile, e-mail or
similar electronic transmission device, as a defense to the formation of this
Agreement.

[Signature pages follow]

    
13

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Investors and the Company have caused this Agreement to
be duly executed as of the 26th day of November, 2014.

COMPANY:
 
ALIMERA SCIENCES, INC.
 
 
By: /s/ Richard S. Eiswirth, Jr.   
Name: Richard S. Eiswirth, Jr.
Title: Chief Operating Officer and Chief Financial Officer
 
 
INVESTORS:

DEERFIELD PRIVATE DESIGN FUND II, L.P.
By: Deerfield Mgmt., L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ David J. Clark            
Name: David J. Clark
Title: Authorized Signatory

DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.
By: Deerfield Mgmt., L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ David J. Clark            
Name: David J. Clark
Title: Authorized Signatory

DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt., L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ David J. Clark            
Name: David J. Clark
Title: Authorized Signatory

    
[Signature Page to Securities Purchase Agreement]

--------------------------------------------------------------------------------

DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.
By: Deerfield Mgmt., L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ David J. Clark            
Name: David J. Clark
Title: Authorized Signatory

DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt. III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ David J. Clark            
Name: David J. Clark
Title: Authorized Signatory

    
[Signature Page to Securities Purchase Agreement]

--------------------------------------------------------------------------------

Schedule 1

Purchase Price Per Share of Series B Preferred Stock    $6,030

Name of Investor
 
Aggregate 
Purchase Price
Number 
of Shares of 
Series B 
Preferred Stock 
to be
Purchased 
by Investor
Pursuant to Section 2(a)*
Number 
of Shares of 
Series B 
Preferred 
Stock 
to be 
Issued to Investor Pursuant to Section 2(b)*
Total
Investor Shares*
Deerfield Private Design
Fund II, L.P.
$
10,485,000
1,738.806
26.082
1,764.888
Deerfield Private Design
International II, L.P.
$
12,015,000
1,992.537
29.888
2,022.425
Deerfield Private Design
Fund III, L.P.
$
22,500,000
3,731.343
55.970
3,787.313
Deerfield Special
Situations Fund, L.P.
$
2,730,000
452.736
6.791
459.527
Deerfield Special Situations
Fund International Limited
$
 2,270,000
   376.451
    5.647
    382.098
   Total:
$
50,000,000
8,291.873*
124.378
8,416.251

_____________
* Each share of Series B Preferred Stock is convertible into 1,000 shares of
Common Stock.

    

--------------------------------------------------------------------------------

Exhibit A

[Certificate of Designation]